Thomas Klöss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas Klöss has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Boris Jansen-Winkeln
Department of Visceral, Transplant, Thoracic and Vascular Surgery , University Hospital of Leipzig , Leipzig , Germany
1 shared publication - Christian Ruckes
Interdisciplinary Center Clinical Trials (IZKS), University Medical Center Mainz, Mainz, Germany
1 shared publication - Claudia Benecke
Surgical Department, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Germany
1 shared publication - Daniel W. Kauff
‡‡Department of General, Visceral, and Vascular Surgery, Hospital Nagold, Nagold, Germany
1 shared publication - Hauke Lang
Department of General, Visceral and Transplant Surgery, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
1 shared publication - Ines Gockel
Department of Visceral Surgery, Clarunis (University Digestive Health Care Center), University Hospital of Basel / St. Clara Hospital of Basel, Switzerland
1 shared publication
Latest Publications
- Open Access
- 22 September 2022
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 277 (4) , e737-e744
Pelvic Intraoperative Neuromonitoring Prevents Dysfunction in Patients With Rectal Cancer
Objective: This NEUROmonitoring System (NEUROS) trial assessed whether pelvic intraoperative neuromonitoring (pIONM) could improve urogenital and ano-(neo-)rectal functional outcomes in patients who underwent total mesorectal excisions (TMEs) for rectal cancer. Background: High-level evidence from clinical trials is required to clarify the benefits of pIONM. Methods: NEUROS was a 2-arm, randomized, controlled, multicenter clinical trial that included 189 patients with rectal cancer who underwent TMEs at 8 centers, from February 2013 to January 2017. TMEs were performed with pIONM (n=90) or without it (control, n=99). The groups were stratified according to neoadjuvant chemoradiotherapy and sex, with blocks of variable length. Data were analyzed according to a modified intention-to-treat protocol. The primary endpoint was a urinary function at 12 months after surgery, assessed with the International Prostate Symptom Score, a patient-reported outcome measure. Deterioration was defined as an increase of at least 5 points from the preoperative score. Secondary endpoints were sexual and anorectal functional outcomes, safety, and TME quality. Results: The intention-to-treat analysis included 171 patients. Marked urinary deterioration occurred in 22/171 (13%) patients, with significantly different incidence between groups (pIONM: n=6/82, 8%; control: n=16/89, 19%; 95% confidence interval, 12.4–94.4; P=0.0382). pIONM was associated with better sexual and ano-(neo)rectal function. At least 1 serious adverse event occurred in 36/88 (41%) in the pIONM group and 53/99 (54%) in the control group, none associated with the study treatment. The groups had similar TME quality, surgery times, intraoperative complication incidence, and postoperative mortality. Conclusion: pIONM is safe and has the potential to improve functional outcomes in rectal cancer patients undergoing TME.
- 22 September 2022
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 277 (4) , e737-e744
Open AccessPelvic Intraoperative Neuromonitoring Prevents Dysfunction in Patients With Rectal Cancer
Objective: This NEUROmonitoring System (NEUROS) trial assessed whether pelvic intraoperative neuromonitoring (pIONM) could improve urogenital and ano-(neo-)rectal functional outcomes in patients who underwent total mesorectal excisions (TMEs) for rectal cancer. Background: High-level evidence from clinical trials is required to clarify the benefits of pIONM. Methods: NEUROS was a 2-arm, randomized, controlled, multicenter clinical trial that included 189 patients with rectal cancer who underwent TMEs at 8 centers, from February 2013 to January 2017. TMEs were performed with pIONM (n=90) or without it (control, n=99). The groups were stratified according to neoadjuvant chemoradiotherapy and sex, with blocks of variable length. Data were analyzed according to a modified intention-to-treat protocol. The primary endpoint was a urinary function at 12 months after surgery, assessed with the International Prostate Symptom Score, a patient-reported outcome measure. Deterioration was defined as an increase of at least 5 points from the preoperative score. Secondary endpoints were sexual and anorectal functional outcomes, safety, and TME quality. Results: The intention-to-treat analysis included 171 patients. Marked urinary deterioration occurred in 22/171 (13%) patients, with significantly different incidence between groups (pIONM: n=6/82, 8%; control: n=16/89, 19%; 95% confidence interval, 12.4–94.4; P=0.0382). pIONM was associated with better sexual and ano-(neo)rectal function. At least 1 serious adverse event occurred in 36/88 (41%) in the pIONM group and 53/99 (54%) in the control group, none associated with the study treatment. The groups had similar TME quality, surgery times, intraoperative complication incidence, and postoperative mortality. Conclusion: pIONM is safe and has the potential to improve functional outcomes in rectal cancer patients undergoing TME.
- 31 January 2012
- Published by Georg Thieme Verlag KG in Der Klinikarzt
- Vol. 41 (01) , 8-10
Entwicklung medizinischer Fachabteilungen – Change Management unter Kostendruck
Im Klinikalltag ist das Thema Change Management meistens angesiedelt im Spannungsfeld zwischen harten Rationalisierungsvorhaben, die stark am unmittelbaren betriebswirtschaftlichen Erfolg orientiert sind und wachstumsorientierten Projekten, die sich mehr auf Veränderung der Kultur oder auf Erneuerung und Innovation konzentrieren. Oft sind diese widersprüchlichen Dynamiken im Projekt zu vereinen [1]. Dies liegt u. a. darin begründet, dass kurzfristige Rationalisierungsmaßnahmen über nachhaltige Kultur- und Organisationsveränderungen in den Kliniken abgesichert werden müssen, damit ein dauerhafter Erfolg der Abteilung sichergestellt werden kann. Ist dies nicht der Fall, folgt Rationalisierung auf Rationalisierung, da das Unternehmen nicht gelernt hat, sich wachstumsorientiert auszurichten. Wie der Balanceakt zwischen konsequenten Einschnitten und neuem Wachstum gestaltet werden kann, zeigt das folgende Praxisbeispiel.
- 31 January 2012
- Published by Georg Thieme Verlag KG in Der Klinikarzt
- Vol. 41 (01) , 8-10
Entwicklung medizinischer Fachabteilungen – Change Management unter Kostendruck
Im Klinikalltag ist das Thema Change Management meistens angesiedelt im Spannungsfeld zwischen harten Rationalisierungsvorhaben, die stark am unmittelbaren betriebswirtschaftlichen Erfolg orientiert sind und wachstumsorientierten Projekten, die sich mehr auf Veränderung der Kultur oder auf Erneuerung und Innovation konzentrieren. Oft sind diese widersprüchlichen Dynamiken im Projekt zu vereinen [1]. Dies liegt u. a. darin begründet, dass kurzfristige Rationalisierungsmaßnahmen über nachhaltige Kultur- und Organisationsveränderungen in den Kliniken abgesichert werden müssen, damit ein dauerhafter Erfolg der Abteilung sichergestellt werden kann. Ist dies nicht der Fall, folgt Rationalisierung auf Rationalisierung, da das Unternehmen nicht gelernt hat, sich wachstumsorientiert auszurichten. Wie der Balanceakt zwischen konsequenten Einschnitten und neuem Wachstum gestaltet werden kann, zeigt das folgende Praxisbeispiel.